Ultragenyx Pharmaceutical Inc. (NASDAQ:RARE) - Equities research analysts at Jefferies Group increased their FY2018 EPS estimates for Ultragenyx Pharmaceutical in a research note issued to investors on Wednesday. Jefferies Group analyst M. Raycroft now forecasts that the biopharmaceutical company will post earnings per share of ($6.41) for the year, up from their previous forecast of ($6.43). Jefferies Group has a “Hold” rating and a $62.00 price objective on the stock. Jefferies Group also issued estimates for Ultragenyx Pharmaceutical’s FY2019 earnings at ($5.86) EPS, FY2020 earnings at ($4.20) EPS and FY2021 earnings at ($2.13) EPS.
RARE has been the topic of several other reports. BidaskClub upgraded Ultragenyx Pharmaceutical from a “sell” rating to a “hold” rating in a research note on Tuesday, June 20th. Stifel Nicolaus reissued a “buy” rating and issued a $111.00 target price on shares of Ultragenyx Pharmaceutical in a report on Friday, June 30th. Sanford C. Bernstein began coverage on Ultragenyx Pharmaceutical in a report on Thursday, July 27th. They issued a “market perform” rating and a $72.00 target price on the stock. HC Wainwright reissued a “neutral” rating and issued a $75.00 target price (up from $72.00) on shares of Ultragenyx Pharmaceutical in a report on Tuesday, August 8th. Finally, Zacks Investment Research downgraded Ultragenyx Pharmaceutical from a “hold” rating to a “sell” rating in a report on Tuesday, July 11th. One analyst has rated the stock with a sell rating, eleven have given a hold rating and eight have assigned a buy rating to the stock. Ultragenyx Pharmaceutical presently has a consensus rating of “Hold” and a consensus target price of $74.82.
TRADEMARK VIOLATION WARNING: “Jefferies Group Analysts Raise Earnings Estimates for Ultragenyx Pharmaceutical Inc. (RARE)” was originally published by StockNewsTimes and is the sole property of of StockNewsTimes. If you are accessing this piece on another publication, it was illegally stolen and reposted in violation of international copyright legislation. The original version of this piece can be accessed at https://stocknewstimes.com/2017/08/26/jefferies-group-analysts-raise-earnings-estimates-for-ultragenyx-pharmaceutical-inc-rare.html.
Ultragenyx Pharmaceutical (NASDAQ:RARE) opened at 51.40 on Friday. Ultragenyx Pharmaceutical has a 12-month low of $50.49 and a 12-month high of $91.35. The firm’s market cap is $2.18 billion. The stock has a 50 day moving average price of $63.00 and a 200-day moving average price of $66.10.
Ultragenyx Pharmaceutical (NASDAQ:RARE) last released its earnings results on Thursday, July 27th. The biopharmaceutical company reported ($1.72) earnings per share (EPS) for the quarter, beating the Zacks’ consensus estimate of ($1.73) by $0.01. During the same period last year, the business posted ($1.46) earnings per share.
Several hedge funds and other institutional investors have recently bought and sold shares of the stock. Ameritas Investment Partners Inc. increased its position in Ultragenyx Pharmaceutical by 7.7% in the second quarter. Ameritas Investment Partners Inc. now owns 3,474 shares of the biopharmaceutical company’s stock worth $216,000 after buying an additional 248 shares during the period. The Manufacturers Life Insurance Company increased its position in Ultragenyx Pharmaceutical by 7.7% in the second quarter. The Manufacturers Life Insurance Company now owns 30,864 shares of the biopharmaceutical company’s stock worth $1,917,000 after buying an additional 2,212 shares during the period. Cubist Systematic Strategies LLC increased its position in Ultragenyx Pharmaceutical by 83.7% in the second quarter. Cubist Systematic Strategies LLC now owns 5,570 shares of the biopharmaceutical company’s stock worth $346,000 after buying an additional 2,538 shares during the period. State Street Corp increased its position in Ultragenyx Pharmaceutical by 21.4% in the second quarter. State Street Corp now owns 1,536,285 shares of the biopharmaceutical company’s stock worth $95,417,000 after buying an additional 270,729 shares during the period. Finally, Cornerstone Capital Management Holdings LLC. increased its position in Ultragenyx Pharmaceutical by 12.7% in the second quarter. Cornerstone Capital Management Holdings LLC. now owns 18,198 shares of the biopharmaceutical company’s stock worth $1,129,000 after buying an additional 2,044 shares during the period. 95.71% of the stock is currently owned by institutional investors.
Ultragenyx Pharmaceutical Company Profile
Ultragenyx Pharmaceutical Inc is a clinical-stage biopharmaceutical company. The Company is focused on the identification, acquisition, development, and commercialization of products for the treatment of genetic diseases. Its clinical-stage pipeline consists of two product categories: biologics (including a monoclonal antibody and an enzyme replacement therapy), and small-molecule substrate replacement therapies.
Receive News & Ratings for Ultragenyx Pharmaceutical Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Ultragenyx Pharmaceutical Inc. and related companies with MarketBeat.com's FREE daily email newsletter.
